The dispute is the latest between the pharmaceutical giant and Imerys Talc America, which filed for bankruptcy in February 2019 to deal with about 15,000 lawsuits alleging its products caused ovarian cancer and asbestos-related mesothelioma. While Imerys, represented by Latham & Watkins, is trying to push forward a plan that would allow it to wrap up the bankruptcy and set up a trust to compensate personal injury claimants, J&J has objected to the deal, saying Imerys is trying to make it easier for cancer victims to sue J&J instead.